GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » BeiGene Ltd (FRA:49BA) » Definitions » Institutional Ownership

BeiGene (FRA:49BA) Institutional Ownership : 24.21% (As of May. 01, 2024)


View and export this data going back to 2016. Start your Free Trial

What is BeiGene Institutional Ownership?

Institutional ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, BeiGene's institutional ownership is 24.21%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, BeiGene's Insider Ownership is 0.00%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, BeiGene's Float Percentage Of Total Shares Outstanding is 0.00%.


BeiGene Institutional Ownership Historical Data

The historical data trend for BeiGene's Institutional Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BeiGene Institutional Ownership Chart

BeiGene Historical Data

The historical data trend for BeiGene can be seen below:

2023-06-30 2023-07-31 2023-08-31 2023-09-30 2023-10-31 2023-11-30 2023-12-31 2024-01-31 2024-02-29 2024-03-31
Institutional Ownership 23.16 23.28 23.57 23.52 22.96 23.05 23.51 23.50 23.63 24.21

BeiGene Institutional Ownership Calculation

The percentage of shares that are owned by institutions out of the total shares outstanding.


BeiGene (FRA:49BA) Business Description

Address
c/o Mourant Governance Services (Cayman) Limited, 94 Solaris Avenue, Camana Bay, Grand Cayman, CYM, KY1-1108
BeiGene Ltd is a commercial-stage biotechnology company. It is engaged in the discovery and development of molecularly targeted and immuno-oncology drugs for the treatment of cancer. The company has developed a proprietary cancer biology platform that addresses the importance of tumor-immune system interactions and the value of primary biopsies in developing new models to support its drug discovery effort. It has developed clinical-stage drug candidates that inhibit the important oncology targets Bruton's tyrosine kinase, or BTK; RAF dimer protein complex and PARP family of proteins, and an immuno-oncology agent that inhibits the immune checkpoint protein receptor PD-1. Its geographical segments are China, the United States, and the Rest of the world.

BeiGene (FRA:49BA) Headlines

No Headlines